## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors:

Jane Hirsh, Kamal Midha, Mark Hirsh and Whe-Yong Lo

Assignee:

Collegium Pharmaceutical, Inc.

Patent No.:

6,863,901

Issue Date:

March 8, 2005

Serial No:

10/015,930

Filed:

November 30, 2001

For:

PHARMACEUTICAL COMPOSITION FOR COMPRESSED ANNULAR TABLET

WITH MOLDED TRITURATE TABLET FOR BOTH INTRAORAL AND ORAL

ADMINISTRATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TERMINAL DISCLAIMER IN ISSUED PATENT

Sir

Petitioner, Collegium Pharmaceutical, Inc., is the owner of the entire interest in the above-identified patent and U.S. Patent No. 6,827,946, issued December 7, 2004, as evidenced by the accompanying Statements Under 37 C.F.R. § 3.73(b). Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of the above-identified patent, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154-156 and 173 as shortened by any terminal disclaimer filed in U.S. Patent No. 6,827,946, or any continuation thereof under 37 C.F.R. § 1.53(b). Petitioner hereby agrees that the above-identified patent shall be enforceable only for and during such period that it and U.S. Patent No. 6,827,946 are commonly owned. This agreement runs with the above-identified patent and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of the above-identified patent that would extend to the expiration date of the full statutory term as

Patent No. 6,863,901 Issued: March 8, 2005

TERMINAL DISCLAIMER IN ISSUED PATENT

defined in 35 U.S.C. §§ 154-156 and 173 of U.S. Patent No. 6,827,946, as shortened by any

terminal disclaimer filed in U.S. Patent No. 6,827,946, in the event that U.S. Patent No.

6,827,946 expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by

a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed

under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is

in any manner terminated prior to the expiration of its full statutory term as shortened by any

terminal disclaimer filed in U.S. Patent No. 6,827,946.

The undersigned (whose title is supplied below) is empowered to act on behalf of

Collegium Pharmaceutical, Inc.

I hereby declare that all statements made herein of my own knowledge are true and that

all statements made on information and belief are believed to be true; and further that these

statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of the application or any

patent issued thereon.

Collegium Pharmaceutical, Inc.

By: \_\_/Rivka D. Monheit/

Name: Rivka D. Monheit, Reg. No. 48,731

Title: Attorney of Record

Date: May 30, 2007

45077144v1

2

CP 104 085337/00007